On July 24, ASCENTAGE fell 5.05% in regular trading, trading at HK$35.32/share, with turnover of HK$38.71 million.

On the news front, the company previously filed an F-3 registration statement with the U.S. SEC on July 20, proposing an at-the-market offering of up to $200 million in American Depositary Shares, with Citi, Deutsche Bank, and BTIG as sales agents. The offering is subject to Hong Kong Stock Exchange waivers from certain listing rules.

Based on the company's current market capitalization of approximately HK$14 billion, the potential $200 million new share issuance poses notable dilution pressure on existing shareholders. Net proceeds are designated for the commercialization of olverembatinib and lisaftoclax, ongoing clinical trials, and working capital. The persistent dilution overhang, combined with broader weakness across the biotech sector, continues to pressure market sentiment surrounding the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)